Plantar Fasciitis Treatment Market Report 2025

The plantar fasciitis treatment market size has grown exponentially in recent years. It will grow from $1.68 billion in 2024 to $2.08 billion in 2025 at a compound annual growth rate (CAGR) of 24%. The growth in the historic period can be attributed to alternative therapies, patient education and awareness, pain management solutions, rise in sports injuries, physical therapy techniques.

The plantar fasciitis treatment market size is expected to see exponential growth in the next few years. It will grow to $4.73 billion in 2029 at a compound annual growth rate (CAGR) of 22.8%. The growth in the forecast period can be attributed to regulatory changes and approvals, patient-centric approaches, research and clinical trials, focus on personalized medicine, growing aging population. Major trends in the forecast period include focused rehabilitation techniques, innovations in orthopedic devices, biomechanical studies, alternative therapies advancements, patient education and self-care.

The increasing prevalence of obesity is expected to drive the growth of the plantar fasciitis market in the future. Obesity is a health concern characterized by an abnormal or excessive accumulation of fat. A body mass index (BMI) of 25 or greater is classified as overweight, while a BMI above 30 is considered obese. Individuals with a normal weight have nearly six times lower chances of developing plantar fasciitis compared to those with a BMI of 30 or higher. For example, data released in 2022 by the Centers for Disease Control and Prevention (CDC), a US government agency, shows that 22 states now report an adult obesity prevalence of 35% or higher, an increase from 19 states in 2021. Thus, the rise in obesity is driving the expansion of the plantar fasciitis market.

The growth of the plantar fasciitis treatment market is anticipated to be propelled by the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, leads to complications such as foot pain and discomfort due to inflammation of the plantar fascia. Plantar fasciitis treatment in diabetes aims to alleviate these symptoms, enhance mobility, and reduce the risk of complications. The IDF Diabetes Atlas reported in 2021 that globally, 537 million people were affected by diabetes, with an estimated 643 million individuals projected to be impacted by 2030 and a significant increase to 783 million by 2045. This surge in diabetes cases is a major driver for the plantar fasciitis treatment market.

Technological advancements are emerging as a prominent trend in the plantar fasciitis treatment market. Leading companies in the market are actively developing and implementing innovative technologies to transform the treatment landscape for plantar heel pain. In December 2022, ZetrOZ Systems introduced the Sam X1, a wireless ultrasound device with FDA certification for at-home usage, offering a regenerative treatment alternative for soft tissue injuries and plantar fasciitis. This device, proven effective in treating various injuries, widens blood vessels to enhance blood flow, promoting healing without drugs or surgery.

Major companies in the plantar fasciitis treatment market are focusing on technological initiatives such as dedicated platforms for accessing global 3D foot scan data. Aetrex, a US-based foot technology company, launched the Foot.com Data Portal in September 2022, providing footwear brands with comprehensive 3D foot scan data to enhance the development of better-fitting shoes. The portal, supported by Aetrex's foot scanners, Albert 2 Pro and Albert 3DFit, offers accurate measurements and assists brands in improving the design of anatomically correct lasts for enhanced comfort and performance.

In October 2022, Patient Square Capital's acquisition of Hanger Inc. for approximately $1.25 billion is a noteworthy development in the plantar fasciitis treatment market. This acquisition is expected to support Hanger in future growth initiatives, particularly in providing innovative and high-quality care through its medical devices, including ankle-foot orthoses (AFO) used in the treatment of plantar fasciitis.

Major companies operating in the plantar fasciitis treatment market include Bayer AG, Superfeet Worldwide LLC, Bauerfeind AG, Ottobock SE & Co. KGaA, Shapecrunch Technology Pvt. Ltd., Sanofi SA, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Scholl’s Wellness Co., Hanger Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Smith & Nephew plc, Arthrex Inc., DJO Global Co., Medline Industries Inc., Bird & Cronin Inc., Aetrex Worldwide Inc.

North America was the largest region in the plantar fasciitis treatment market in 2024. The regions covered in the plantar fasciitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plantar fasciitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plantar fasciitis treatment involves medical care or preventive measures aimed at assessing the occurrence and frequency of a degenerative condition affecting the thick band of tissue at the base of the foot. An integral aspect of treating plantar fasciitis is physical therapy.

The primary categories of plantar fasciitis treatment include medication therapy, orthotics, shockwave therapy, surgery, and other interventions. Medication therapy involves treating the condition using prescription or non-prescription medicines, over-the-counter medications, and herbal remedies. Diagnosis typically relies on medical history, physical examination, X-rays, radiography, and other diagnostic methods and is administered by hospitals, clinics, and other healthcare providers.

The plantar fasciitis treatment market research report is one of a series of new reports that provides plantar fasciitis treatment market statistics, including plantar fasciitis treatment industry global market size, regional shares, competitors with a plantar fasciitis treatment market share, detailed plantar fasciitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the plantar fasciitis treatment industry. This plantar fasciitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plantar fasciitis treatment market includes revenues earned by entities by provide extracorporeal shock wave therapy (ESWT), intracorporeal pneumatic shock wave therapy (IPST), inflammation-related pain drugs, and non-operative treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.